Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study

Jorge F. Saucedo, Mark B. Effron(Eli Lilly (United States)), Dominick J. Angiolillo(University of Florida), Andrew L. Frelinger(University of Nottingham), Clement K. Ojeh(Eli Lilly (United States)), Timothy M. Costigan(Eli Lilly (United States)), Paul A. Gurbel(Sinai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Roger DeRaad(Black Hills Center for American Indian Health)
Queensland's institutional digital repository (The University of Queensland)
November 3, 2009
Cited by 1

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
|Circulation|2017|745
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651